Ionis Pharmaceuticals Inc (IONS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $4.84B
Last updated: Nov 17, 2026 at 4:38 PM ET
Ionis Pharmaceuticals Inc (IONS) Statistics
Ionis Pharmaceuticals (IONS) has a market cap of $4.84B and an enterprise value of $6.13B. It kept -56.93% of revenue as net income over the last 12 months. Its share count is up 4.03% from a year earlier.
Total Valuation
Enterprise value is 26.66% above the market cap, as debt exceeds cash.
| Market Cap | $4.84B |
|---|---|
| Enterprise Value | $6.13B |
| Latest price (Nov 17, 2026) | $26.96 |
Key Dates
The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 23, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 4.7x and 11.4x. Its year-end P/S ranged from 5.7x to 15.7x from 2016 to 2025.
| P/S Ratio | 4.7x |
|---|---|
| Forward P/S | 5.3x |
| P/B Ratio | 11.4x |
Price Statistics
The stock is down 62.32% over 52 weeks and trades 36.50% below its 50-day average.
| Beta (1Y) | 0.34 |
|---|---|
| 52-Week Change | -62.32% |
| 1-Month Change | -39.25% |
| 3-Month Change | -55.66% |
| 6-Month Change | -63.49% |
| 5-Year Change | +36.55% |
| 10-Year Change | +67.51% |
| Total Return (1Y) | -62.32% |
| Total Return (3Y CAGR) | -18.04% |
| Total Return (5Y CAGR) | -3.46% |
| Return vs SPY (1Y) | -75.37% |
| Max Drawdown (1Y) | -68.83% |
| Max Drawdown (3Y) | -68.83% |
| Sharpe Ratio (1Y) | -1.97 |
| Correlation with SPY (1Y) | 0.09 |
| 50-Day Average | $42.46 |
| 200-Day Average | $63.94 |
| 52-Week Range | $27.25 to $86.74 |
| RSI (14 Days) | 21.7 |
| Average Volume (20 Days) | 4.79M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.43x current liabilities, and total debt is 4.03x shareholder equity.
| Current Ratio | 5.43x |
|---|---|
| Quick Ratio | 5.36x |
| Debt / Equity | 4.03x |
| Interest Coverage | -7.63x |
Returns and Efficiency
Return on invested capital is -29.31% over the last 12 months, against a 5-year average of -19.27%.
| Return on Equity (ROE) | -138.84% |
|---|---|
| Return on Assets (ROA) | -18.76% |
| Return on Invested Capital (ROIC) | -29.31% |
| ROE (5Y Average) | -60.13% |
| ROA (5Y Average) | -9.98% |
| ROIC (5Y Average) | -19.27% |
| Asset Turnover | 0.32x |
| Inventory Turnover | 0.43x |
| Receivables Turnover | 13.05x |
| Cash Conversion Cycle | 77 days |
Scores
IONS has an Altman Z-Score of 0.12, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.12 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $960.09M over the last 12 months is down 0.71% from the 12 months before.
| Revenue | $960.09M |
|---|---|
| Revenue Growth (YoY) | -0.71% |
| Gross Profit | $943.09M |
| Operating Income | -$564.88M |
| Pretax Income | -$543.72M |
| Net Income | -$546.54M |
| Reported EPS (TTM) | -$2.81 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 13.53% of the $2.91B in total assets.
| Cash and Equivalents | $296.30M |
|---|---|
| Total Debt | $1.59B |
| Net Debt | $1.29B |
| Net Debt Per Share | $7.76 |
| Working Capital | $1.93B |
| Shareholder Equity | $393.64M |
| Book Value Per Share | $2.37 |
| Total Assets | $2.91B |
| Total Liabilities | $2.52B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $71.85M of capital spending, operating cash flow left -$616.26M of free cash flow.
| Operating Cash Flow | -$544.41M |
|---|---|
| Capital Expenditures | $71.85M |
| Free Cash Flow | -$616.26M |
| FCF Per Share | -$3.71 |
| Depreciation and Amortization | $20.03M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -58.84%, against a 5-year average of -45.26%.
| Gross Margin | 98.23% |
|---|---|
| Operating Margin | -58.84% |
| Pretax Margin | -56.63% |
| Net Margin | -56.93% |
| FCF Margin | -64.19% |
| Gross Margin (5Y Average) | 98.36% |
| Operating Margin (5Y Average) | -45.26% |
| Net Margin (5Y Average) | -40.15% |
Growth
Revenue grew 17.12% a year over 3 years.
| Revenue Growth (3Y CAGR) | +17.12% |
|---|---|
| Revenue Growth (5Y CAGR) | +5.29% |
| Book Value Per Share Growth (2Y CAGR) | +6.60% |
| Tangible Book Per Share Growth (2Y CAGR) | +6.60% |
Dividends and Yields
IONS does not pay a dividend. Its free cash flow yield is -13.75%.
| FCF Yield | -13.75% |
|---|---|
| Buyback Yield | -4.71% |
| Shareholder Yield | -4.71% |
Peer Position
Against 6 similar companies, IONS has the 6th highest P/S and the 3rd highest ROIC.
P/S RatioPeer median 16.1x
ROICPeer median -52.22%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +1.03%
| P/S Ratio | 4.7x vs 16.1x median |
|---|---|
| ROIC | -29.31% vs -52.22% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -0.71% vs +1.03% median |
Analyst Forecast
Consensus estimates put revenue growth at 12.53% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +12.53% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IONS
What is IONS's market cap?
Ionis Pharmaceuticals has a market cap of $4.84B. Its enterprise value, which adds debt and subtracts cash, is $6.13B.
How many shares of IONS are outstanding?
Ionis Pharmaceuticals has 166.21M shares outstanding. The count is up 4.03% from a year earlier.
Does IONS pay a dividend?
No. Ionis Pharmaceuticals does not pay a dividend.
How much debt does IONS have?
Ionis Pharmaceuticals has $1.59B of total debt and $296.30M of cash and equivalents, a net debt position of $1.29B.
IONS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors